NCT04041011View on ClinicalTrials.gov

A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 17, 2019

Primary Completion Date

April 23, 2021

Study Completion Date

April 23, 2021

Conditions
Small Cell Lung Cancer
Interventions
DRUG

1.Experimental: A (Part 1): Fluzoparib and SHR -1316

1．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).

DRUG

2.Experimental: B (Part 1): Fluzoparib and SHR -1316

2．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).

DRUG

3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion

3．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).

Trial Locations (1)

310005

Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04041011 - A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients | Biotech Hunter | Biotech Hunter